McKesson

McKesson plans to acquire Precision Medicine Group for $2.25 billion to add oncology-focused CRO, clinical-trial and market-access capabilities to its Oncology and Multi-Specialty segment, subject to regulatory approval. The company reported strong first-quarter results, with North American Pharmaceutical Distribution revenue up ~5% and Oncology and Multi-Specialty revenue and profit rising about 33% and 41%, respectively. McKesson expects to return roughly $5 billion to shareholders this year, including $2.5 billion in buybacks and a 15% dividend increase, while continuing investments in automation, AI and other growth initiatives. The firm is also progressing with the separation of its Medical-Surgical business, rebranded as Wellverse, targeted for the back half of next year. » Plus sur finance.yahoo.com

McKesson will acquire Precision Medicine Group for about $2.25 billion to expand its Oncology & Multispecialty business with clinical research, lab testing and commercialization services. The deal aligns with McKesson's strategy of exiting non-core assets and investing in higher-growth specialty and oncology areas. Management expects the acquisition to strengthen clinical trial execution and biopharma offerings, but no closing timeline was provided and integration, scalability and near-term earnings impact remain uncertain. » Plus sur finance.yahoo.com

McKesson has signed a definitive agreement to acquire Precision Medicine Group for about $2.25 billion, a move investors view as expanding its oncology and multispecialty strategy. Precision Medicine Group provides clinical research services, biomarker analysis, laboratory services and commercialization support for biotech and pharma companies. The acquisition follows a restructuring that refocused McKesson on higher-margin, faster-growing areas; its oncology and multispecialty business recently grew by 33%. analyst backing and a dividend increase have supported the positive market reaction; the stock rose sharply intraday and is approaching its 52-week high. » Plus sur de.investing.com